US 11,814,382 B2
Crystal form as ASK1 inhibitor and preparation method and application thereof
Shengbin Zhang, Shanghai (CN); Ning Li, Shanghai (CN); Tao Yu, Shanghai (CN); Yusheng Fu, Shanghai (CN); Jiahu Wu, Shanghai (CN); and Chengde Wu, Shanghai (CN)
Assigned to FUJIAN AKEYLINK BIOTECHNOLOGY CO., LTD., Fujian (CN)
Appl. No. 17/260,565
Filed by FUJIAN COSUNTER PHARMACEUTICAL CO., LTD., Fujian (CN)
PCT Filed Jul. 19, 2019, PCT No. PCT/CN2019/096678
§ 371(c)(1), (2) Date Jan. 15, 2021,
PCT Pub. No. WO2020/015721, PCT Pub. Date Jan. 23, 2020.
Claims priority of application No. 201810806190.4 (CN), filed on Jul. 20, 2018.
Prior Publication US 2021/0269441 A1, Sep. 2, 2021
Int. Cl. C07D 471/04 (2006.01)
CPC C07D 471/04 (2013.01) [C07B 2200/13 (2013.01)] 16 Claims
 
1. Crystal form A of a compound of formula (I) having an X-ray powder diffraction (XRPD) pattern with characteristic diffraction peaks at 2θ angles: 8.40±0.2°, 13.46±0.2°, and 14.13±0.2°,

OG Complex Work Unit Chemistry